Good News: CSIR- CCMB develops a specific drug for COVID-19 treatment

The CSIR- Centre for Cellular and Molecular Biology has developed, possibly the first specific drug for COVID-19 treatment, which contain therapeutic antibodies.

The Drug Controller General of India (DGCI) has given its approval for human trials, Phase-I and Phase-II for the VINCOV-19 and expected to be tried next week in Delhi and Rajasthan.

Developed by the CCMB, University of Hyderabad and Vins Bioproduct ltd combine, the VINCOV-19 is a collection of antibodies from Horses after they got injected inactivated Corona virus.

CCMB Director Dr Rakesh K Mishra said to AIR our that the approval for its emergency use by the India's Drug Regulator is expected once the results of phase I and II declared.

He exuded confidence that it may take 3-4 weeks for getting approval for emergency use.

He further said the VINCOV may be the first specific drug for COVID treatment and it works best when given on early stage of infection.